Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Esomeprazole Sodium

FDA-approved product (injectable, intravenous), marketed as Esomeprazole Magnesium, Nexium, Nexium 24hr and 3 more.

Registered studies
46
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Esomeprazole Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ankylosing spondylitis
  • Duodenal ulcer
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Rheumatoid arthritis
  • Zollinger-Ellison Syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Proton pump inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Esomeprazole Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Esomeprazole Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

    NCT00660660 · start 2008-04

    Registered record
    Registry ID
    NCT00660660
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    Esomeprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2008-07
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionEsomeprazole; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

    NCT00734097 · start 2007-11

    Registered record
    Registry ID
    NCT00734097
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    Esomeprazole 40 mg; Physical Exam; Quality of Life Questionnaires; pregnancy test, if applicable
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-11
    Completion
    2008-10
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    InterventionEsomeprazole 40 mg; Physical Exam; Quality of Life Questionnaires; pregnancy test, if applicable
    PhasePhase 4
    Registry statusCompleted

  • Phase 3/Safety & Efficacy of Esomeprazole in Infants

    NCT00468559 · start 2007-04

    Registered record
    Registry ID
    NCT00468559
    Conditions
    Gastroesophageal Reflux Disease (GERD)
    Interventions
    Open Label Run In Esomeprazole; Double Blind Esomeprazole; Double Blind Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-06
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease (GERD)
    InterventionOpen Label Run In Esomeprazole; Double Blind Esomeprazole; Double Blind Placebo
    PhasePhase 3
    Registry statusCompleted

  • Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

    NCT00474903 · start 2007-04

    Registered record
    Registry ID
    NCT00474903
    Conditions
    Barrett Esophagus; Esophageal Cancer
    Interventions
    acetylsalicylic acid; esomeprazole magnesium; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-04
    Completion
    2011-06
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBarrett Esophagus; Esophageal Cancer
    Interventionacetylsalicylic acid; esomeprazole magnesium; placebo
    PhasePhase 2
    Registry statusCompleted

  • Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

    NCT00443963 · start 2006-12

    Registered record
    Registry ID
    NCT00443963
    Conditions
    Dyspepsia
    Interventions
    Esomeprazole Magnesium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2006-12
    Completion
    2006-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspepsia
    InterventionEsomeprazole Magnesium
    PhasePhase 4
    Registry statusWithdrawn

  • Symptom Adapted Therapy in GERD Patients

    NCT00343161 · start 2006-08

    Registered record
    Registry ID
    NCT00343161
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    esomeprazole; Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-08
    Enrolment
    441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    Interventionesomeprazole; Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)

    NCT00687245 · start 2006-08

    Registered record
    Registry ID
    NCT00687245
    Conditions
    Endoscopically-Proven GERD; Reflux
    Interventions
    esomeprazole magnesium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2008-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndoscopically-Proven GERD; Reflux
    Interventionesomeprazole magnesium
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

    NCT00317044 · start 2006-04

    Registered record
    Registry ID
    NCT00317044
    Conditions
    Asthma; GERD
    Interventions
    Esomeprazole; Esomeprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2008-07
    Enrolment
    961

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; GERD
    InterventionEsomeprazole; Esomeprazole; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

    NCT00206024 · start 2004-11

    Registered record
    Registry ID
    NCT00206024
    Conditions
    Heartburn
    Interventions
    Esomeprazole magnesium (Nexium)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-11
    Completion
    2005-07
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn
    InterventionEsomeprazole magnesium (Nexium)
    PhasePhase 4
    Registry statusCompleted

  • NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

    NCT00206180 · start 2004-06

    Registered record
    Registry ID
    NCT00206180
    Conditions
    Erosive Esophagitis; Reflux Esophagitis; Gastroesophageal Reflux Disease
    Interventions
    esomeprazole magnesium (oral medication)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-08
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErosive Esophagitis; Reflux Esophagitis; Gastroesophageal Reflux Disease
    Interventionesomeprazole magnesium (oral medication)
    PhasePhase 4
    Registry statusCompleted

  • Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

    NCT00079833 · start 2003-11

    Registered record
    Registry ID
    NCT00079833
    Conditions
    Zollinger-Ellison Syndrome
    Interventions
    Esomeprazole magnesium (Nexium)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2005-07
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionZollinger-Ellison Syndrome
    InterventionEsomeprazole magnesium (Nexium)
    PhasePhase 3
    Registry statusCompleted

  • A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

    NCT00641602 · start 2002-12

    Registered record
    Registry ID
    NCT00641602
    Conditions
    Erosive Esophagitis
    Interventions
    Esomeprazole; Lansoprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2003-08
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErosive Esophagitis
    InterventionEsomeprazole; Lansoprazole
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)

    NCT00637845 · start 2002-06

    Registered record
    Registry ID
    NCT00637845
    Conditions
    Heartburn; Gastroesophageal Reflux Disease
    Interventions
    Esomeprazole Magnesium; Lansoprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-06
    Completion
    2003-02
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn; Gastroesophageal Reflux Disease
    InterventionEsomeprazole Magnesium; Lansoprazole
    PhasePhase 4
    Registry statusCompleted

  • Barrett's Esophagus - 315 - 3 Way Cross-Over

    NCT00637559 · start 2002-03

    Registered record
    Registry ID
    NCT00637559
    Conditions
    Barrett's Esophagus
    Interventions
    Esomeprazole Magnesium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2003-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBarrett's Esophagus
    InterventionEsomeprazole Magnesium
    PhasePhase 4
    Registry statusCompleted

  • Prevention of Gastric Ulcers

    NCT00629512 · start 2001-03

    Registered record
    Registry ID
    NCT00629512
    Conditions
    NSAID Associated Gastric Ulcers
    Interventions
    Esomeprazole; Esomeprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-03
    Completion
    2002-12
    Enrolment
    504

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSAID Associated Gastric Ulcers
    InterventionEsomeprazole; Esomeprazole; Placebo
    PhasePhase 3
    Registry statusCompleted